Community Health Media

As the ADC landscape expands, how is datopotamab deruxtecan redefining the treatment paradigm for both breast and lung cancer?In this episode of CHM Conversations, Dr. Megan Kruse and Dr. Lukas Delasos break down the clinical integration of next-generation ADCs. The discussion differentiates the roles of ADCs such as datopotamab deruxtecan and trastuzumab deruxtecan, examining their impact across HER2-directed and Trop-2 targeted settings in both metastatic breast cancer and thoracic oncology.Beyond the data, the clinicians share practical insights on navigating sequencing challenges, resistance mechanisms, and the evolving role of biomarkers in personalizing care. A major focus is placed on proactive toxicity management, highlighting essential protocols to ensure treatment continuity and optimize patient outcomes.A strategic resource for oncology clinicians navigating the future of ADC therapy, biomarker-guided treatment selection, and precision oncology across breast and lung cancer.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #LungCancer #NSCLC #ADC #AntibodyDrugConjugates #HER2Low #EGFR #DatopotamabDeruxtecan #TrastuzumabDeruxtecan #PrecisionOncology #TargetedTherapy #MedicalOncology #ThoracicOncology #BreastOncology #ILD #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

The second-line landscape for HR+/HER2- metastatic breast cancer is shifting rapidly with the detection of truncal mutations. In this episode of CHM Conversations, Dr. Ruta Rao and Dr. Azadeh Nasrazadani discuss how the detection of PIK3CA, AKT, and PTEN mutations is redefining the role of capivasertib.The clinicians differentiate the clinical application of capivasertib from other targeted agents like alpelisib and inavolisib, exploring how mechanistic differences and biomarker profiles influence patient selection. A central focus is placed on mastering the safety profile of these agents, providing practical strategies for managing stomatitis, diarrhea, and hyperglycemia to ensure treatment continuity and optimize patient outcomes.An essential resource for oncology teams navigating the complexities of the PI3K/AKT/PTEN pathway and optimizing supportive care in the second-line metastatic breast cancer landscape.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #HRPositive #MetastaticBreastCancer #PrecisionOncology #BiomarkerTesting #PIK3CA #ESR1 #Capivasertib #LiquidBiopsy #EndocrineTherapy #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

How is Dato-DXd redefining first-line mTNBC? In this episode of CHM Conversations, Dr. Hope Rugo and Dr. Rebecca Shatsky discuss the TROPION-Breast02 trial results and how this data fits into the broader landscape alongside the ASCENT-03 findings.The clinicians focus on the shift toward frontline Trop2-directed strategies and how these agents are challenging the chemotherapy-only paradigm. They also address the practicalities of management—specifically managing stomatitis and ocular toxicity while navigating CNS disease and supportive care.An essential resource for oncology clinicians navigating the future of precision ADC therapy in triple-negative breast cancer.🎧 Watch more expert-led oncology conversations from CHM Conversations.#TripleNegativeBreastCancer #TNBC #MetastaticBreastCancer #ADCtherapy #SacituzumabGovitecan #DatopotamabDeruxtecan #Trop2 #BreastOncology #MedicalOncology #PrecisionOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Can earlier ESR1 mutation detection help delay progression and preserve quality of life? In this episode of CHM Conversations, Dr. Hope Rugo and Dr. Rebecca Shatsky discuss the evolving role of oral SERDs and ctDNA monitoring in HR+ mBC.The conversation centers on the SERENA-6 trial and the strategy of identifying ESR1 mutations before radiographic progression. Dr. Rugo and Dr. Shatsky explore how intervening earlier with camizestrant—while maintaining the CDK4/6 inhibitor backbone—may prolong progression-free survival and delay the transition to more intensive chemotherapy or ADCs.The clinicians examine how these mutations develop as acquired resistance and discuss the broader shift away from the traditional “wait for progression” approach. They also address the real-world logistics of precision medicine, including testing frequency, quantitative monitoring, and the potential to reduce the frequency of traditional scans.A valuable discussion for oncology clinicians navigating endocrine resistance and the future of biomarker-driven care in metastatic breast cancer.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #MetastaticBreastCancer #HRPositive #HER2Negative #ESR1 #OralSERD #Camizestrant #SERENA6 #ctDNA #LiquidBiopsy #PrecisionOncology #CDK46 #EndocrineTherapy #PIK3CA #TargetedTherapy #MedicalOncology #BreastOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

How are clinicians navigating the complex balance between immunotherapy and antibody-drug conjugates? In this episode of CHM Conversations, Dr. Neil Iyengar and Dr. Ticiana Leal discuss the integration of Dato-DXd into the rapidly evolving treatment paradigms for breast and lung cancer.The experts break down the practicalities of sequencing these therapies, moving beyond traditional chemotherapy to determine where ADCs fit alongside immunotherapy and other targeted agents. The discussion covers everything from biomarker-driven selection to the proactive management of toxicities like ILD and ocular effects, providing a roadmap for optimizing long-term sequencing and patient quality of life.An essential watch for oncology clinicians managing the integration of next-generation targeted therapies into modern clinical practice.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #LungCancer #NSCLC #ADC #AntibodyDrugConjugates #DatopotamabDeruxtecan #TrastuzumabDeruxtecan #TROP2 #HER2 #EGFR #TargetedTherapy #PrecisionOncology #MedicalOncology #ThoracicOncology #BreastOncology #Immunotherapy #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Can molecular monitoring help clinicians intervene earlier to extend the benefit of first-line therapy? In this episode of CHM Conversations, Dr. Neil Iyengar, Dr. Manali Bhave, and Dr. Reshma Mahtani discuss overcoming resistance in HR+ mBC.The conversation focuses on the SERENA-6 trial and the strategy of using serial ctDNA monitoring to catch ESR1 mutations before radiographic progression. Dr. Neil Iyengar, Dr. Manali Bhave, and Dr. Reshma Mahtani break down the practicalities of sequencing endocrine therapies and other targeted therapies, and specifically how a proactive switch to camizestrant may delay the transition to chemotherapy.Beyond the data, the clinicians address real-world challenges—from navigating insurance and workflow logistics to managing the emotional impact of "molecular progression" and side effects like photopsia.An essential update for oncology clinicians looking to optimize treatment sequencing and patient quality of life.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #MetastaticBreastCancer #HRPositive #HER2Negative #ESR1 #Camizestrant #SERENA6 #OralSERD #ctDNA #LiquidBiopsy #PrecisionOncology #CDK46 #EndocrineTherapy #PIK3CA #TargetedTherapy #MedicalOncology #BreastOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Are we moving past the traditional "wait for progression" model in HR+ mBC? In this episode of CHM Conversations, Dr. Megan Kruse and Dr. Carol Tweed examine how molecular resistance monitoring is redefining the treatment timeline.The discussion highlights the shift toward a proactive approach, focusing on the clinical utility of serial ctDNA testing as seen in the SERENA-6 trial. Dr. Kruse and Dr. Tweed discuss how identifying ESR1 mutations early allows for a more precise transition to oral SERDs, helping to preserve endocrine sensitivity and delay the need for more aggressive ADC or chemotherapy regimens.The clinicians also dive into the nuances of sequencing endocrine therapies and other targeted therapies, and specifically how molecular data helps time the move to next-generation agents. They address the "real-world" side of precision medicine—from implementing liquid biopsy workflows and navigating insurance to managing patient anxiety and monitoring for treatment-related side effects.A valuable perspective for oncology clinicians looking to master the next generation of biomarker-driven care.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #MetastaticBreastCancer #HRPositive #HER2Negative #ESR1 #OralSERD #Camizestrant #SERENA6 #ctDNA #LiquidBiopsy #PrecisionOncology #TargetedTherapy #EndocrineTherapy #CDK46 #ADC #MedicalOncology #BreastOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

What if we could change treatment before scans show progression? In this episode of CHM Conversations, Dr. Jason Mouabbi and Dr. Ahmed Elkhanany explore the impact of ESR1 mutations and the clinical shift toward "molecular progression" in HR+ mBC.The discussion breaks down the SERENA-6 trial and how early ctDNA detection may allow clinicians to switch therapy before radiologic progression occurs. Dr. Mouabbi and Dr. Elkhanany highlight how precision oncology is reshaping strategy, specifically looking at how oral SERDs like camizestrant can extend endocrine sensitivity and delay more intensive treatments.The clinicians also examine the transition away from traditional RECIST-based decision-making. They address the practicalities of routine ctDNA testing, patient communication, and what community oncologists should expect as these biomarker-driven approaches move closer to standard practice.A compelling discussion on the future of proactive intervention and earlier care in metastatic breast cancer.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #HRPositive #Oncology #ESR1 #ctDNA #SERENA6 #Camizestrant #EndocrineTherapy #PrecisionOncology #MedicalOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

How are clinicians navigating the growing number of targeted therapy options in HR-positive, HER2-negative metastatic breast cancer?In this CHM Conversations episode, Drs. Rebecca Shatsky and Reva Basho discuss the critical role of genomic profiling—specifically PIK3CA, AKT, PTEN, and ESR1—in guiding second-line treatment for HR+/HER2- metastatic breast cancer.The panel compares the clinical use of alpelisib, capivasertib, and inavolisib, focusing on how to sequence these agents after progression on CDK4/6 inhibitors. The experts share practical strategies for managing class-specific toxicities and discuss the future of oral SERDs and combination therapies in personalizing patient care.A valuable discussion for oncologists and healthcare professionals navigating precision medicine and targeted sequencing strategies in breast oncology.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #MetastaticBreastCancer #HRPositive #HER2Negative #Oncology #PIK3CA #AKT #PTEN #Capivasertib #Alpelisib #Inavolisib #ctDNA #PrecisionOncology #TargetedTherapy #MedicalOncology #BreastOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

How are clinicians optimizing the use of AKT inhibitors in HR-positive metastatic breast cancer?In this CHM Conversations episode, Drs. Neil Iyengar, Manali Bhave, and Reshma Mahtani explore the shifting second-line landscape for HR+/HER2- metastatic breast cancer. The discussion centers on the clinical integration of capivasertib and the necessity of biomarker testing—specifically PIK3CA, AKT, PTEN, and ESR1—following progression on CDK4/6 inhibitors.The panel emphasizes a proactive approach to toxicity, detailing how multidisciplinary care and early metabolic optimization can mitigate class-specific side effects like hyperglycemia, rash, and diarrhea. By focusing on patient education and glycemic control from the start of the treatment journey, clinicians can effectively balance the potent efficacy of PI3K/AKT/PTEN pathway inhibition with long-term tolerability.A valuable discussion for oncology clinicians navigating biomarker-driven care and targeted therapy management in metastatic breast cancer.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #MetastaticBreastCancer #HRPositive #HER2Negative #Oncology #PIK3CA #AKT #PTEN #Capivasertib #Truqap #PrecisionOncology #TargetedTherapy #EndocrineTherapy #MedicalOncology #BreastOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

How is molecular profiling reshaping HR+ metastatic breast cancer treatment?In this episode of CHM Conversations, Dr. Erica Mayer and Dr. Seth Wander navigate the evolving landscape of endocrine resistance and the PI3K/AKT pathway. They discuss the shifting roles of ESR1 and PIK3CA mutations, the rise of ctDNA in clinical sequencing, and the practicalities of integrating newer therapies like capivasertib.From proactive toxicity monitoring to the future of combination care, this discussion explores the next era of precision medicine in HR+ breast cancer.An essential resource for clinicians navigating the future of endocrine therapy and targeted treatment strategies.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #HRPositive #Oncology #PIK3CA #ESR1 #ctDNA #Capivasertib #EndocrineTherapy #PrecisionOncology #MedicalOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Can early intervention change the course of metastatic HR+ breast cancer?In this expert discussion, Dr. Seth Wander and Dr. Erica Mayer break down the practice-changing SERENA-6 trial and the emerging role of camizestrant in ESR1-mutated metastatic breast cancer.From ctDNA monitoring and early resistance detection, to quality-of-life improvements and precision endocrine therapy—they explore how oral SERDs may redefine treatment sequencing in HR-positive, HER2-negative disease.Topics include:• SERENA-6 trial design and results• ESR1 mutations and endocrine resistance• ctDNA-guided treatment decisions• Quality-of-life outcomes with camizestrant • Oral SERDs vs aromatase inhibitors• The future of precision endocrine therapy🎧 Watch now on Community Health Media.#BreastCancer #HRPositive #ESR1 #Camizestrant #SERENA6 #Oncology #BreastOncology #PrecisionOncology #ctDNA #OralSERD #MetastaticBreastCancer #CancerResearch #MedicalOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

In this special Spanish-language episode, experts Dr. Ricardo Alvarez, Dr. Marcela Mazo-Canola, and Dr. Ana Sandoval-Leon sit down to discuss the breakthroughs transforming modern breast oncology.The panel explores how personalized medicine is redefining outcomes and quality of life across the spectrum of HER2-positive, triple-negative, and hormone receptor-positive breast cancers. From the integration of genomic testing and liquid biopsies to the rise of antibody-drug conjugates (ADCs), this discussion covers the frontline of clinical practice.Topics include:• Advances in HER2+ and triple-negative breast cancer• Genomic testing and liquid biopsy• ADCs and targeted therapies• CDK4/6 inhibitors and PARP inhibitors• Immunotherapy and emerging treatment strategies• Clinical trials and access to care in Latin America• Toxicity management and quality of life• The future of personalized breast cancer treatmentAn essential conversation for oncologists, healthcare professionals, and patients interested in the future of breast cancer care — presented entirely in Spanish.▶️ Subscribe for more expert oncology conversations.–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

What happens when breast and thoracic oncology collide over the future of ADCs?In this cross-specialty conversation, Dr. Jason Mouabbi and Dr. Eric Singhi explore how antibody-drug conjugates are reshaping both breast and lung cancer treatment. From T-DXd and datopotamab deruxtecan to HER2-low disease, EGFR-mutated NSCLC, ILD management, sequencing strategies, and the future of combination ADC therapy — this episode dives deep into the rapidly evolving world of precision oncology.They discuss:• Why ADCs are transforming metastatic care• Managing ILD, stomatitis, ocular toxicity, and nausea• Sequencing ADCs and resistance mechanisms• Combining ADCs with immunotherapy and targeted therapy• HER2-low, ultra-low, and biomarker-driven treatment strategies• How breast and lung oncology are learning from each other🎧 A must-watch conversation on the next era of targeted cancer therapy.#BreastCancer #LungCancer #ADCs #TDXd #DatopotamabDeruxtecan #HER2Low #EGFR #PrecisionOncology #ThoracicOncology #MedicalOncology #CancerResearch #OncologyPodcast #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

What if we could detect endocrine resistance before it shows up on scans?In this CHM Conversations episode, Dr. Sigrun Hallmeyer and Dr. William Gradishar break down the SERENA-6 trial and what it means for the future of HR-positive, HER2-negative metastatic breast cancer.From early detection of ESR1 mutations using ctDNA to switching therapy before clinical progression, this discussion explores how molecular monitoring is reshaping treatment decisions, extending progression-free survival, and preserving quality of life.The conversation also dives into real-world implementation, patient experience, cost considerations, and what comes next as oncology moves toward more personalized, biology-driven care.A must-watch for clinicians navigating the evolving endocrine landscape.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #HRPositive #Oncology #ESR1 #ctDNA #SERENA6 #EndocrineTherapy #MedicalOncology #PrecisionOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

The HER2-positive landscape is undergoing its most significant shift in over a decade!In this in-depth CHM Conversations episode, VK Gadi and Tarah Ballinger break down the practice-changing data behind DB09, PATINA, HER2CLIMB-05, DB05, and DB11 — and what these trials mean for real-world patient care.This deep dive explores the critical transition from traditional maintenance habits to optimized ADC persistence—balancing unprecedented efficacy with rigorous safety standards and ILD monitoring. From the potential for durable responses in metastatic disease to the expanding role of ADCs in early-stage neoadjuvant and adjuvant settings, this discussion provides a comprehensive roadmap for the entire patient journey.A must-watch conversation for oncologists, researchers, and anyone following the next era of HER2-directed therapy.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #HER2Positive #TDXd #DESTINYBreast09 #Oncology #MedicalOncology #CancerResearch #PrecisionOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

In this expert discussion, Dr. VK Gadi and Dr. Ruta Rao break down the data that’s reshaping treatment for HER2-positive breast cancer — from DESTINY-Breast 05 and 11 to the first-line metastatic implications of DESTINY-Breast 09.They explore what the numbers really mean for patients with residual disease, how CNS risk and toxicity factor into decision-making, and where T-DXd may (or may not) replace existing standards of care.A candid, data-driven conversation for clinicians navigating HER2+ treatment today — and preparing for what comes next.#HER2Positive #BreastCancer #TDXd #Oncology #CancerResearch #ESMO #ASCO #MedicalOncology #PrecisionMedicine #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Recorded live, this in-depth conversation features Dr. Irene Kang and Dr. Aditya Bardia breaking down the DESTINY-Breast09 data and what it means for first-line treatment of metastatic HER2-positive breast cancer.From challenging the long-standing THP standard to unpacking unprecedented progression-free survival, higher complete response rates, and CNS activity with T-DXd, this discussion explores how and why first-line decision-making is evolving. The panel also dives into patient selection, toxicity management, ILD monitoring, dose optimization, induction vs maintenance strategies, and how to frame these advances in real-world patient conversations.A must-watch for clinicians navigating the next era of HER2-positive metastatic breast cancer care.#HER2Positive #BreastCancer #DESTINYBreast09 #TDXd #Oncology #MedicalOncology #BreastOncology #CancerResearch #ClinicalTrials #PrecisionOncology #ESMO #ASCO #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Recorded with Drs. Neil Iyengar and Komal Jhaveri, this in-depth discussion breaks down the most practice-shifting data in early-stage HER2-positive breast cancer — from neoadjuvant to adjuvant decision-making.The conversation explores DESTINY-Breast11 and its unprecedented pathologic complete response rates with sequential T-DXd followed by THP, including an 83% pCR in hormone receptor–negative disease. The panel also examines safety, ILD risk, anthracycline-free strategies, and how these results may reshape neoadjuvant standards.The discussion then moves to DESTINY-Breast05, where T-DXd demonstrated superiority over T-DM1 in the residual disease setting, with a hazard ratio of 0.5 for invasive disease-free survival — raising critical questions about patient selection, CNS recurrence, and curative intent strategies.A must-watch episode for clinicians navigating the rapidly evolving HER2-positive landscape.#BreastCancer #HER2Positive #EarlyStageBreastCancer #Oncology #MedicalOncology #DESTINYBreast11 #DESTINYBreast05 #TDXd #AntibodyDrugConjugates #NeoadjuvantTherapy #AdjuvantTherapy #CancerResearch #ClinicalTrials #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Recorded live with Drs. Gregory Vidal and Nusayba Bagegni, this in-depth conversation tackles one of the most provocative questions in HER2-positive metastatic breast cancer today: are we finally approaching cure?The discussion spans more than a decade of progress — from the CLEOPATRA regimen and its long tail of durable responders to the practice-changing data from DESTINY-Breast09 showing a 40-month progression-free survival with T-DXd plus pertuzumab.The panel explores how Patina, HER2CLIMB-05, endocrine therapy integration, CNS disease, and patient-specific risk factors are reshaping first-line decision-making. With more options than ever before, this episode highlights why precision, sequencing, and shared decision-making now define HER2-positive care.#BreastCancer #HER2Positive #MetastaticBreastCancer #Oncology #MedicalOncology #DESTINYBreast09 #PatinaTrial #HER2CLIMB #TDXd #AntibodyDrugConjugates #PrecisionOncology #CancerResearch #ClinicalTrials #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Recorded live, this in-depth conversation features Dr. Alison Conlin and Dr. Heather McArthur as they break down the evolving role of antibody–drug conjugates in early-stage HER2-positive breast cancer.The discussion dives into DESTINY-Breast 11 and DESTINY-Breast 05, exploring how trastuzumab deruxtecan is challenging long-standing neoadjuvant and adjuvant paradigms. From pathologic complete response and invasive disease-free survival to toxicity management, ILD monitoring, and patient selection, this episode tackles how clinicians are balancing escalation and de-escalation in curative-intent care.A thoughtful, practical conversation on where HER2-positive treatment is headed — and how today’s decisions may redefine cure for high-risk patients.#BreastCancer #HER2Positive #Oncology #EarlyBreastCancer #DB11 #DB05 #AntibodyDrugConjugates #TrastuzumabDeruxtecan #NeoadjuvantTherapy #AdjuvantTherapy #ClinicalTrials #PrecisionOncology #MedicalOncology–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

For more than a decade, the Cleopatra regimen transformed outcomes in HER2-positive metastatic breast cancer — delivering landmark overall survival gains and redefining long-term disease control.Recorded at SABCS, this expert roundtable features Dr. Bill Gradishar, Dr. Tarah Ballinger, and Dr. Megan Kruse as they examine how the HER2 landscape is evolving in the era of antibody–drug conjugates.The discussion explores the real-world impact of DESTINY-Breast09, the role of trastuzumab deruxtecan (T-DXd) in the first-line setting, and how clinicians are balancing efficacy, toxicity, and quality of life. From induction vs maintenance strategies to emerging data from PATINA and HER2CLIMB-05, this conversation highlights the nuance required in modern HER2+ decision-making.🎧 A must-watch conversation on progress, uncertainty, and shared decision-making in HER2-positive metastatic breast cancer.#HER2Positive #MetastaticBreastCancer #BreastCancer #Oncology #DESTINYBreast09 #TDXd #CleopatraTrial #AntibodyDrugConjugates #MedicalOncology #BreastOncology #SABCS #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Recorded live around the latest data from SABCS, ASCO, and ESMO, this in-depth conversation features Dr. Mark Pegram and Dr. Carol Tweed examining whether the long-standing Cleopatra regimen is finally giving way to a new first-line standard in HER2-positive metastatic breast cancer.From Destiny-Breast09 and unprecedented progression-free survival results to response depth, CNS considerations, and the real-world implications of continuous ADC therapy, this discussion breaks down what the data truly mean for patient care.The conversation also explores induction vs. maintenance strategies, the role of endocrine therapy and CDK4/6 inhibitors, quality-of-life tradeoffs, pneumonitis risk, and how clinicians are navigating shared decision-making in an era of rapidly evolving options.A must-watch episode for oncologists preparing for what may be the biggest first-line shift in HER2-positive metastatic disease in over a decade.#BreastCancer #HER2Positive #MetastaticBreastCancer #Oncology #DestinyBreast09 #TrastuzumabDeruxtecan #ADCs #CleopatraRegimen #BreastOncology #CancerResearch #ClinicalTrials #MedicalOncology #PrecisionOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

For more than a decade, CLEOPATRA defined first-line therapy in HER2-positive metastatic breast cancer.Now, DESTINY-Breast09 is forcing a fundamental rethink.In this in-depth roundtable, Drs. Neil Iyengar, Komal Jhaveri, and Igor Makhlin examine:• The legacy — and limitations — of CLEOPATRA• DESTINY-Breast09’s unprecedented ~40-month PFS• When T-DXd + pertuzumab should move to the frontline• Patient selection, toxicity management, and ILD vigilance• Sequencing strategies after frontline ADCs• How maintenance paradigms may evolveA must-watch discussion on efficacy vs durability, escalation vs personalization, and what “best therapy first” truly means in 2025.#HER2Positive #BreastCancer #Oncology #DESTINYBreast09 #TDXd #AntibodyDrugConjugates #CLEOPATRA #MetastaticBreastCancer #MedicalOncology #PrecisionOncology #ASCO #ESMO–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Recorded at SABCS 2025, Dr. Neil Iyengar and Dr. Martin Dietrich break down the data that may finally dethrone CLEOPATRA as the long-standing first-line standard for HER2-positive metastatic breast cancer.From the historic success of dual HER2 inhibition to the game-changing DESTINY-Breast09 results showing median PFS exceeding 40 months, this conversation explores what true progress looks like — and how it should change clinical practice.They dive into brain metastases risk, durability of response, toxicity management, patient selection, and why using the most effective therapy first may no longer be optional.🎧 A must-watch discussion on evidence-based change in the HER2+ treatment landscape.#HER2Positive #BreastCancer #MetastaticBreastCancer #Oncology #SABCS2025 #DESTINYBreast09 #TDXd #AntibodyDrugConjugates #ADCs #BreastOncology #CancerResearch #ClinicalTrials #PrecisionOncology #MedicalOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Recorded live at ASCO 2025, Amy Krie, Mabel Mardones, and Anne O'Dea break down the data that could redefine first-line treatment for HER2-positive metastatic breast cancer.From the legacy of CLEOPATRA to the stunning DB09 results showing median PFS exceeding 40 months, this expert roundtable explores what this shift means in real-world practice.They tackle patient selection, CNS metastases, toxicity management, dose reductions, and how using the most effective drug first is what is most ethically imperative.🎧 A must-watch discussion on efficacy, quality of life, and how clinicians should navigate this rapidly changing HER2+ landscape.#BreastCancer #HER2Positive #MetastaticBreastCancer #Oncology #ASCO2025 #DB09 #TDXd #AntibodyDrugConjugates #ADCs #BreastOncology #CancerResearch #ClinicalTrials #PrecisionOncology #MedicalOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Recorded at the 2025 San Antonio Breast Cancer Symposium, Dr. Mark Pegram (Stanford University) and Dr. Fengting Yan (Swedish Cancer Institute) break down the data that may redefine first-line treatment for HER2-positive metastatic breast cancer.This expert discussion dives deep into DESTINY-Breast09, exploring unprecedented progression-free survival results with T-DXd + pertuzumab, implications for brain metastases, response durability, toxicity management, and whether the long-standing CLEOPATRA regimen is finally being challenged.From induction–maintenance strategies to personalized treatment selection, this conversation offers real-world clinical insight into what’s next for HER2+ disease.🎧 A must-watch for oncologists navigating the next era of HER2-targeted therapy.#HER2Positive #BreastCancer #MetastaticBreastCancer #TDXd #DestinyBreast09 #CLEOPATRA #Oncology #MedicalOncology #BreastOncology #ADC #AntibodyDrugConjugates #SABCS2025 #CancerResearch #ClinicalTrials–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

In this deep-dive conversation, Dr. Bill Gradishar and Dr. Tiffany Traina break down two pivotal first-line trials reshaping treatment for metastatic triple-negative breast cancer.They explore TROPION-Breast02 and ASCENT-03, unpacking progression-free survival, overall survival, response rates, toxicity profiles, and what truly differentiates datopotamab deruxtecan from sacituzumab govitecan in real-world practice.From refractory disease and disease-free interval definitions to logistics, crossover design, brain metastases, and patient-centered decision-making, this discussion offers practical insight into how clinicians should think about therapy selection, sequencing, and shared decision-making in mTNBC today.🎧 A must-watch episode for oncologists navigating the rapidly evolving TNBC treatment landscape.#TripleNegativeBreastCancer #TNBC #Oncology #BreastCancer #AntibodyDrugConjugates #ADCs #Datopotamab #Sacituzumab #CancerResearch #MedicalOncology #ClinicalTrials #PrecisionOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

In this in-depth conversation, Dr. Jason Mouabbi, Dr. Joyce O’Shaughnessy, and Dr. Mothaffar Rimawi unpack the data that may redefine first-line treatment for HER2-positive metastatic breast cancer.From DESTINY-Breast 09 to real-world decision-making, they discuss what a 40-month median PFS truly means, how T-DXd compares to THP, and whether “if it ain’t broke, don’t fix it” still applies.They also tackle sequencing strategies, maintenance vs continuous therapy, PIK3CA resistance, and how patient quality of life is shaping long-term treatment decisions.A must-watch episode for clinicians navigating the rapidly evolving HER2+ landscape.#HER2Positive #BreastCancer #TDXd #Oncology #MetastaticBreastCancer #CancerResearch #PrecisionOncology #MedicalOncology #ESMO #ASCO #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Recorded live at ESMO 2025 in Berlin, this expert roundtable features Drs. Adam Brufsky, VK Gadi, Ian Krop, Neil Iyengar, Paolo Tarantino, Giancarlo Moscol, Shanu Modi, and Maryam Lustberg as they tackle the most pressing questions shaping breast cancer care today.From HER2-low and ultra-low disease to antibody–drug conjugates, trial interpretation, sequencing strategies, and what truly defines “best first therapy,” this conversation cuts through the noise with real-world clinical insight.With perspectives on T-DXd, emerging ADCs, evolving biomarkers, and patient-centered decision-making, the discussion offers a forward-looking view of where breast oncology is headed — and what clinicians need to prepare for now.🎧 A must-watch conversation on the science, strategy, and nuance behind the next era of breast cancer treatment.#BreastCancer #Oncology #ESMO2025 #HER2 #HER2Low #AntibodyDrugConjugates #ADCs #TDXd #BreastOncology #CancerResearch #ClinicalTrials #PrecisionOncology #MedicalOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Triple-negative breast cancer has entered a new era.At ESMO 2025, TRO-Breast02 and ASCENT-03 delivered practice-shifting data — from rapid progressors to PD-L1–defined pathways and the growing role of TROP2-targeted ADCs.Dr. Neil Iyengar and Dr. Erika Hamilton break down trial design differences, crossover implications, toxicity management, and how these results will shape first-line treatment decisions for TNBC.#BreastCancer #TNBC #TripleNegativeBreastCancer #TROP2 #ADCs #TDXd #SacituzumabGovitecan #ASCENT03 #TROB02 #ESMO2025 #Oncology #CancerResearch #CHM–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

The landscape of HER2+ and HER2-low breast cancer is shifting fast — and DB-05 and DB-11 are at the center of it.In this deep-dive from ESMO 2025, Dr. Gregory Vidal and Dr. Erika Hamilton break down what the latest T-DXd data means for real-world practice, how ILD should be monitored, and why sequencing matters more than ever.#BreastCancer #HER2 #HER2Low #TDXd #TrastuzumabDeruxtecan #ESMO2025 #DB05 #DB11 #OncologyEducation #CancerResearch #MedicalOncology #CHM–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

At ESMO Berlin, Dr. Mark Pegram and Dr. Ana Garrido-Castro break down breakthrough data shaping the new standard for first-line metastatic triple-negative breast cancer (TNBC).Together, they unpack results from ASCENT-03 and TROPION-Breast02, where Trop-2 antibody-drug conjugates demonstrated significant improvements in response rates, PFS, and — in one study — overall survival.Drs. Pegram and Garrido-Castro explore:• Why Trop-2 ADCs may replace chemotherapy in PD-L1–negative TNBC• Key differences in trial design, patient selection, and endpoints• Real-world decision-making based on toxicity, dosing schedules, and prophylaxis• How HR-low disease, BRCA/PALB2 status, and CNS involvement factor into treatment strategyA must-listen for clinicians navigating the fast-evolving landscape of metastatic TNBC and the rise of ADC-driven precision therapy.#BreastCancer #TNBC #TripleNegativeBreastCancer #ESMO2025 #OncologyPodcast #Trop2 #ADCtherapy #CancerResearch #ClinicalOncology #BreastOncology #PrecisionOncology #CHM –Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Achieving pCR has long been considered the “holy grail” in HER2+ breast cancer — but does it truly guarantee protection from recurrence, especially in the brain?In this conversation, Drs. Jason Mouabbi, Irene Kang, and Ruemu Birhiray explore evolving perspectives on pCR, CNS relapse, and the emerging role of neratinib in protecting high-risk patients. They discuss new data, the unmet need for CNS-active strategies, and how upcoming trials like DESTINY-Breast05 and COMPASS-HER2 RD could redefine the adjuvant landscape.Watch to understand what’s next for HER2+ disease — and how oncologists are rethinking long-term protection beyond pathologic complete response.📺 Subscribe to Community Health Media for more expert-led oncology conversations.🎧 Stream the full episode on Spotify, Apple Podcasts, or YouTube.#BreastCancer #HER2Positive #Oncology #BreastCancerResearch #BreastCancerAwareness #Neratinib #Trastuzumab #CancerCare #MedicalOncology #CancerResearch #CHM #CommunityHealth #Podcast #ClinicalOncology #AdjuvantTherapy #CancerEducation–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

From testing to treatment, the conversation around PARP inhibition in breast cancer is rapidly evolving.In this episode, Dr. Neil Iyengar and Dr. Mark Robson explore how germline testing, risk stratification, and therapy sequencing are shaping adjuvant treatment decisions for BRCA1/2-mutated breast cancer.They discuss:🔹 Who should be tested — and how testing criteria are expanding.🔹 Key takeaways from OlympiA and long-term data on olaparib.🔹 The balance between PARP inhibitors, CDK4/6 inhibitors, and IO-based regimens.🔹 How toxicity, sequencing, and emerging biomarkers like MRD may guide the future of adjuvant therapy.Stay ahead of the data in this forward-looking conversation on personalizing care for high-risk HER2-negative breast cancer.📺 Subscribe to Community Health Media and stream the full conversation on YouTube, Spotify, or your favorite podcast platform.#CommunityHealthMedia #BreastCancerResearch #AdjuvantTherapy #PARPInhibitors #Olaparib #OlympiAStudy #BRCA #OncologyPodcast #BreastOncology #CancerCare #PrecisionOncology #OncologyEducation–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Direct from ESMO 2025 in Berlin, Dr. Mark Pegram and Dr. Neil Iyengar unpack what many are calling a new standard in HER2-directed therapy.From DESTINY-Breast 11’s practice-changing neoadjuvant results to DESTINY-Breast 05 in the adjuvant setting — and now DESTINY-Breast 09 rewriting the metastatic playbook — the data are clear: trastuzumab deruxtecan (T-DXd) is transforming treatment across disease stages.The discussion moves beyond HER2 + disease into HER2-low and ultra-low, touching on how new definitions, ADC sequencing, and precision testing could expand eligibility to the majority of breast cancers.🎧 Tune in for a high-impact, expert-level recap of the trials defining the next chapter of HER2 oncology.#BreastCancer #ESMO2025 #OncologyPodcast #HER2Positive #HER2Low #TDXd #Pegram #Iyengar #TrastuzumabDeruxtecan #CancerResearch #BreastOncology #PrecisionOncology #CHM–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Watch this enlightening conversation focused on the transforming power of antibody-drug conjugates (ADCs) like T-DXd (trastuzumab deruxtecan) in HER2-positive breast cancer therapy with Dr. Anne O’Dea and Dr. VK Gadi. The doctors provide hope for T-DXd’s potential usage as a first-line treatment, which could change present guidelines away from conventional chemotherapy treatments like the Cleopatra regimen, notable for their high toxicity. Effective, focused therapy with less side effects provided by T-DXd could improve patients’ quality of life and maybe increase general survival.They also discuss the value of HER2 testing, pointing out that patients labeled as HER2-low or ultra-low could still benefit from T-DXd , therefore stressing the need of more exact diagnostic criteria. Trials like DB12 and DESTINY-Breast06 under progress allow Dr. O’Dea and Dr. Gadi optimism for improved understanding of ideal therapy sequencing, particularly for managing brain metastases—a major difficulty in HER2-positive cases.Emphasizing personalizing, strategic sequencing, and future research to generate better outcomes and, finally, the possibility for more curative medicines, their discussion shows an emerging approach to HER2 treatment.🎧 Don’t forget to like, share, and subscribe for more CHM Conversations#BreastCancer #OncologyPodcast #TDXd #HER2Low #CHMConversations #PrecisionMedicine #CancerResearch–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Join Dr. VK Gadi and Dr. Jason Mouabbi at a recent conference for their discussion around the changing function of antibody-drug conjugates (ADCs) such as T-DXd (trastuzumab deruxtecan) in treating HER2-positive breast cancer, especially in patients with central nervous system (CNS) metastases. The talk hinges on the historical use of tiny compounds like tucatinib to ensure they’re able to pass the blood-brain barrier. New research, however, challenges the conventional wisdom on treatment restrictions by showing that ADCs might also be useful in this environment.Dr. Mouabbi offered a real-world illustration of T-DXd’s transforming power by sharing a clinical case whereby it produced amazing regression of both visceral and central nervous system disorders. Data from studies like as DESTINY-Breast04 and the forthcoming DB12 study, which concentrates on patients with untreated or stable brain metastases, could provide vital direction on T-DXd’s efficacy in CNS care. In line with the encouraging findings observed in clinical practice, this trial seeks to confirm T-DXd’s influence on brain metastases.The discussion also touches on the need for closely monitoring patients, especially for possible side effects including interstitial lung disease (ILD), with doctors using routine CT imaging and pulmonary function testing. Dr. Mouabbi underlined that novel treatments such as T-DXd represent a turning point in the field and give patients with metastatic breast cancer hitherto unheard-of hope.You can watch the full conversation between Dr. Gadi and Dr. Mouabbi below to hear more of their experience and analysis of how ADCs are changing HER2-positive breast cancer treatment, therefore offering patients with advanced illness more focused and efficient choices.🎧 Don’t forget to like, share, and subscribe for more CHM Conversations#BreastCancer #OncologyPodcast #TDXd #HER2Low #CHMConversations #PrecisionMedicine #CancerResearch–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

What happens when MD Anderson’s translational firebrand Jason Mouabbi sticks a microphone in front of long-time HER2 guru Mothaffar Rimawi just days after the first read-out of DESTINY-Breast09? In sixty candid minutes they chart how trastuzumab deruxtecan (T-DXd) ± pertuzumab vaulted past CLEOPATRA; posting a headline 41-month PFS that forces oncologists to rethink induction/maintenance dogma, sequencing, and even the forbidden word “cure.” in what was previously considered uncurable. Along the way they debate ILD fears, whether any patient should ever leave the clinic without concurrent endocrine therapy, and christen T-DXd as “the great equalizer” for tumors burdened by ESR1, PIK3CA or BRCA mutations. By the end, Dr. Rimawi’s motto “put your best player in at kickoff” feels less like a bravado and more like the tomorrow’s standard of care.Why you’ll want to listen • Design matters: how DB-09’s two experimental arms (T-DXd alone vs T-DXd + pertuzumab) were built to settle the dual-blockade question once and for all. • A 41-month shockwave: the largest PFS ever seen in metastatic HER2-positive breast cancer—and why it may still climb. • Induction vs “until further notice”: can oncologists still offer a chemo-free maintenance phase, or does the ADC stay on forever? • ILD in real life: 12 % remains, but community doctors already trade scheduled breaks for lower risk without sacrificing depth of response. • Sequencing after an early ADC: if T-DXd moves up front, what’s left for tucatinib, T-DM1 or neratinib and more importnatly does it matter? • Cure? Dare we say it: Rimawi argues we are “closest in any solid tumor” to normal life expectancy; Dr. Mouabbi pushes him to define what bold looks like. • Endocrine cross-talk—still ignored: fewer than 10 % of DB-09 patients got concomitant endocrine therapy despite 60 % ER-positivity, a missed chance the speakers vow to fix. • PI3K mutation? Payload doesn’t care: why the ADC’s topoisomerase warhead levels the playing field across resistance genotypes. 🎧 Like, share, and subscribe for more CHM Conversations that turn headline data into bedside decisions.#BreastCancer #HER2Positive #TDXd #DESTINYBreast09 #OncologyPodcast #PrecisionMedicine #CHMConversations–Thanks for listening!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

What happens when an MD Anderson breast oncology investigator Dr. Mouabbi sits down with a high-volume community oncologist Dr. Cairo, who now treats the same patients the trials were written for? Over one fast-moving hour, they chart the collapse of the old HER2 binary, weigh DESTINYBreast 04 against 06, and admit that practicing oncologists still hesitate to jump straight from endocrine therapy to trastuzumab deruxtecan (TDXd) when trusty capecitabine is sitting on the shelf. They swap war stories about persuading pathology to report “ultralow” staining, debate whether any historical 1+ slide is enough to warrant an ADC, and reveal why “whichever ADC you give first is going to be your best ADC.” The conversation converges into ILD pragmatics, that is, community clinicians, it seems, aren’t the least bit afraid before landing on a new term the duo coined on air: “endocrine dynamics,” that is, the art of cycling back to hormones once the aggressive clone is beaten down by an ADC.Highlights you’ll hear: the trial-by-trial evolution from DB04 to DB06 and why ultralow tumors now matter; capecitabine versus the allure of earlier ADCs; ultralow testing bottlenecks and the coming ASCOCAP guideline shakeup; sequencing philosophies (sandwich vs back-to-back) and their payload implications; real-world ILD management that’s less daunting than advertised; and, at the close, a playful wager on whether we’ll soon treat every HR-positive case as “ADC-eligible” until true zero is finally defined.🎧 Listen, share, and subscribe for more CHM Conversations that fuse bigtrial evidence with the front lines#BreastCancer #HER2Low #Ultralow #TDXd #ADCSequencing #OncologyPodcast #CHMConversations–Thanks for listening!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

When the binary “HER2-positive vs HER2-negative” model collapsed under the weight of DESTINY-Breast04 and 06, the real work began: deciding who should receive trastuzumab deruxtecan (T-DXd), when to leapfrog chemotherapy, and how to keep quality of life front-and-center. In this interactive Live from Seattle stream, translational researcher & clinician Dr. V.K. Gadi and high-volume breast oncologist Dr. Fengting Yan wrestle with that nuance in front of a virtual audience. Drawing on SABCS sub-analyses, ASCO 2025 biomarker updates, and their own experience and anecdotes, they outline a decisional playbook that blends disease-burden triage, endocrine-resistance patterns, and the evolving spectrum of HER2 testing from IHC 3+ to “ultralow” 0.1 %.Whether you manage trials, beds, or databases, this hour distills the fast-moving ADC landscape into pragmatic rules of thumb and flags the knowledge gaps that still separate evidence from art.Topics include: • HER2 re-imagined: from a rigid binary to a four-tier lexicon (positive, low, ultralow, zero) and why pathologists now add “ultralow” to reports. • DESTINY-Breast04 vs 06 head-to-head: why chemo-naïve, HR-positive patients doubled objective response (57 % vs 32 %) and what that means for first post-endocrine standard of care. • Disease-burden triage: T-DXd first for “angry livers” and visceral-crisis lung mets; oral agents still reasonable for indolent bone-only progressors. • Endocrine exhaustion vs sub-optimal use: ESR1 mutation, shrinking ER staining, and ≤6-month PFS as triggers to skip another endocrine line and go straight to an ADC. • Sequencing before traditional chemo: weighing physician-choice capecitabine against IV T-DXd after DB-06 — and the lingering fear of closing off later options. • Safety & survivorship: keeping ILD in check while troubleshooting weight-gain, nausea, and fatigue before cutting the dose. • ADC-after-ADC Sandwich? emerging data on payload switching and why some clinicians are abandoning the “sandwich” doctrine to front-load the most active agents. • Real-world evidence 2.0: how AI-curated registries are validating clinical-trial deltas across messy geographies and comorbidity spectra. • Future watch-list: DB-09, NeoCARHP and biomarker-guided de-escalation trials, e.g. ATEMPT 2.0 that might finally limit indefinite therapy.🎧 Like, share, and subscribe for more CHM Conversations that translate headline data into bedside decisions#BreastCancer #HER2Low #Ultralow #TDXd #OncologyPodcast #CHMConversations–Thanks for listening!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

In this insightful CHM Conversations episode, Drs. Callahan & Bardia delve deep into the evolving definitions of HER2 positivity (and negativity, or lack of HER2) in breast cancer and the transformative impact of trastuzumab deruxtecan (T-DXd) especially in metastatic cases. From groundbreaking historical discoveries to recent clinical trial advancements, they critically examine how HER2 classifications, have moved on from binary to a continuum from low to even ultra-low expression and are reshaping therapeutic paradigms and patient care decisions. Key insights into managing brain metastases, T-DXd associated pneumonitis, optimizing treatment sequencing, and effectively communicating complex medical data to patients highlight the conversation. This episode is essential listening for oncologists, researchers, and advocates interested in the latest shifts in breast cancer therapy.Topics Covered: • Historical evolution of HER2 classifications • Clinical impact of HER2 low and ultra-low categorizations • DESTINY-Breast trials and groundbreaking T-DXd data • Management strategies for brain metastases, T-DXd associated pneumonitis • Patient-centered communication and shared decision-making🎧 Don’t forget to like, share, and subscribe for more CHM Conversations#HER2 #TDXd #MetastaticBreastCancer #BreastCancerResearch #OncologyEducation #CHMConversations #DESTINYBreast04 #FirstLineTherapy #CancerCare–Thanks for listening!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

In this episode of CHM Conversations, two of breast oncology’s brightest specialists — Dr. Jason Mouabbi and Dr. Paolo Tarantino — explore how trastuzumab deruxtecan (T-DXd) has fundamentally restructured therapeutic strategies across HER2-positive and HER2-low disease, while “curing” what was once thought to be really aggressive disease. From the transformative DESTINY-Breast trials to the evolving art of real-world clinical decision-making, they dissect not only the science and trial data but the shifting frameworks now guiding oncologists at the bedside.They critically examine how T-DXd, once a remarkable agent for refractory HER2+ tumors, is now reshaping standards in HER2-low and ultra-low settings, overcoming historical binaries of HER2 classification. Their conversation traverses management of brain metastases, individualized sequencing to mitigate ILD risks, and emerging strategies to move away from indefinite therapy models. Importantly, they emphasize the growing need for precision-driven, patient-centered oncology at a time when therapeutic options are expanding faster than rigid guidelines can adapt.Whether you're a healthcare provider, researcher, or patient advocate, this is a must-listen episode that offers deep insight into one of the most promising advances in breast cancer therapy.🔬 Topics include:• The T-DXd era: from preclinical promise to clinical breakthrough• Reframing HER2 biology: Low and ultra-low as therapeutic targets, not distinct entities• Management of brain metastases• Strategic dominance in metastatic disease: DESTINY-Breast03, 04, 06, and 12 insights• Sequencing treatment strategies and minimizing ILD risk• Minimizing ILD risk: The Five S's — Screen, Scan, Synergy, Suspend, Steroids• The future of early-stage disease: Neoadjuvant and adjuvant trials challenging classical chemotherapy models🎧 Don’t forget to like, share, and subscribe for more CHM Conversations#BreastCancer #OncologyPodcast #TDXd #HER2Low #CHMConversations #PrecisionMedicine #CancerResearch–Thanks for listening!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media